Coherus BioSciences Inc. (NASDAQ:CHRS)’s share price was up 3.8% during trading on Wednesday . The company traded as high as $26.22 and last traded at $25.64, with a volume of 118,596 shares trading hands. The stock had previously closed at $24.70.

A number of brokerages have issued reports on CHRS. Zacks Investment Research downgraded Coherus BioSciences from a “hold” rating to a “sell” rating in a research report on Thursday, May 12th. Citigroup Inc. began coverage on Coherus BioSciences in a research report on Wednesday. They set a “buy” rating and a $36.00 price objective on the stock. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $32.60.

The firm has a 50 day moving average of $18.82 and a 200 day moving average of $18.04. The firm’s market cap is $1.01 billion.

Coherus BioSciences (NASDAQ:CHRS) last announced its quarterly earnings results on Monday, May 9th. The company reported ($1.67) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.42) by $0.25. Analysts anticipate that Coherus BioSciences Inc. will post ($5.90) EPS for the current year.

In related news, insider Alan C. Herman sold 4,250 shares of Coherus BioSciences stock in a transaction dated Monday, May 2nd. The stock was sold at an average price of $19.20, for a total value of $81,600.00. Following the completion of the transaction, the insider now owns 207,167 shares in the company, valued at approximately $3,977,606.40. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Peter K. Watler sold 3,991 shares of Coherus BioSciences stock in a transaction dated Thursday, July 21st. The shares were sold at an average price of $26.13, for a total value of $104,284.83. Following the completion of the transaction, the insider now owns 3,991 shares of the company’s stock, valued at approximately $104,284.83. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Coherus BioSciences stock. Brown Advisory Inc. boosted its stake in Coherus BioSciences Inc. (NASDAQ:CHRS) by 3.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 200,918 shares of the company’s stock after buying an additional 5,937 shares during the period. Brown Advisory Inc. owned about 0.52% of Coherus BioSciences worth $4,614,000 at the end of the most recent quarter.

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.